BioSpace News Archive

Ventyx Biosciences, Inc. announced that it will report financial results for the first quarter ended March 31, 2023 after market close on May 11, 2023.

Mersana Therapeutics, Inc. announced that on May 1, 2023, an authorized sub-committee of the Board of Directors of Mersana granted inducement awards, consisting of stock options to purchase an aggregate of 77,550 shares of its common stock and restricted stock unit awards to acquire an aggregate of 65,715 shares of its common stock, to four new employees whose employment commenced in April 2023.

Immuneering Corporation, a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, reported financial results for the first quarter ended March 31, 2023, and provided business updates.

Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, announced that the Company intends to release its first quarter 2023 financial results on Monday, May 15, 2023.

Acumen Pharmaceuticals, Inc. announced that management will participate in a fireside chat at the 2023 Bank of America Healthcare Conference on Thursday, May 11, 2023 at 8:00 a.m. PT.

Crinetics Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2023.

Codexis, Inc., a leading enzyme engineering company, announced financial results for the first quarter ended March 31, 2023, and provided a business update.

Eledon Pharmaceuticals, Inc. announced that it plans to release financial results for the first quarter ended March 31, 2023 on Thursday, May 11, after the close of trading.

Ambrx Biopharma Inc., or Ambrx, announced the appointment of Andrew P. Aromando as Chief Operating Officer.

Schrödinger, Inc., whose physics-based computational platform is transforming the way therapeutics and materials are discovered, announced financial results for the first quarter ended March 31, 2023.